Azafaros B.V. announced in January 2023 that it Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA) to conduct a clinical Phase 2 trial for its lead asset, AZ-3102, for the treatment of GM2 gangliosidosis (GM2) and Niemann-Pick disease type C (NP-C). In addition to the IND clearance, the FDA …
Category
Showing: 1 - 3 of 7 RESULTS
Banner News
IntraBio Completes Recruitment for IB1001 NPC Pivotal Clinical Trial
OXFORD, UK / December 08, 2022 / IntraBio Inc announced today that it has completed recruitment for its Pivotal Trial, Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study (IB1001-301 – NCT05163288). Enrolment for IB1001-301 commenced in September 2022. Patients were screened across 13 multinational trial sites …
DART to The Finish Charity Walk Raises $175,000
The fifth annual DART to The Finish charity walk benefitting Dana’s Angels Research Trust (DART) took place Saturday, September 24, 2022, at Greenwich Point Park in Old Greenwich, and virtually across the country. More than 300 participated and helpedraised more than $175,000, which will go towards supporting crucial research into better treatments, clinical trials and …